Announcements Trials
Browse Landscape

Phase

Phase 2/3 1

Status

Completed 1

Sponsor Class

NETWORK 1

Study Type

Interventional 1

Sponsor

Conditions

Breast Neoplasms 6Triple Negative Breast Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Recurrent Squamous Cell Lung Carcinoma 1Recurrence 1Prostatic Neoplasms 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Oligodendroglioma 1Neoplasms, Neuroepithelial 1Neoplasm Metastasis 1Multiple Myeloma 1Medulloblastoma 1Lymphoma, T-Cell 1Lymphoma, Non-Hodgkin 1Leukemia, T-Cell 1Leukemia, Lymphoid 1Glioblastoma 1Choroid Plexus Neoplasms 1CCND1 Gene Amplification 1Breast Neoplasm Female 1Breast Cancer Recurrent 1Astrocytoma 1

Interventions

palbociclib 1Docetaxel 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NETWORK × CCND1 Gene Amplification × palbociclib × Clear all
NCT02785939 2021-05-27

Lung-MAP: Palbociclib as Second-Line Therapy in Treating Cell Cycle Gene Alteration Positive Patients With Recurrent Stage IV Squamous Cell Lung Cancer

SWOG Cancer Research Network

Phase 2/3 Completed
53 enrolled 15 charts

CCND1 Gene Amplification

Data powered by HemOnc (CC BY 4.0) Colophon âš¡